National Bank Of Canada Bellus Health Inc. Transaction History

National Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 12, 2023	BUY	$7.14 - $8.53 $570,950 - $682,101	79,965 Added 7.49%	1,147,145 $8.26 Million
Q4 2022 Jan 24, 2023	BUY	$8.22 - $10.76 $8.6 Million - $11.3 Million	1,045,639 Added 4854.18%	1,067,180 $0
Q3 2022 Oct 13, 2022	SELL	$8.95 - $12.0 $56,653 - $75,960	-6,330 Reduced 22.71%	21,541 $226,000
Q2 2022 Jul 28, 2022	SELL	$6.46 - $10.02 $13,055 - $20,250	-2,021 Reduced 6.76%	27,871 $268,000
Q1 2022 May 05, 2022	BUY	$5.56 - $7.99 $15,567 - $22,372	2,800 Added 10.34%	29,892 $203,000
Q4 2021 Jan 24, 2022	BUY	$5.26 - $8.3 $142,503 - $224,863	27,092 New	27,092 $214,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

Stay updated on National Bank Of Canada with notifications on news.